Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.9144.2223
Address
Level 20 Tower A, The Zenith 821 Pacific Highway Chatswood, New South Wales (NSW) 2067
Description
Noxopharm Ltd. engages in the research and development of drugs. It focuses on sensitizing cancer cells to radiotherapy and chemotherapy. The company was founded by Graham Kelly on October 27, 2015 and is headquartered in Chatswood, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.17
Trade Value (12mth)
AU$8,939.00
1 week
-2.78%
1 month
1.45%
YTD
-7.89%
1 year
79.49%
All time high
1.59
EPS 3 yr Growth
2475.000%
EBITDA Margin
N/A
Operating Cashflow
-$11m
Free Cash Flow Return
-66.00%
ROIC
-90.70%
Interest Coverage
-401.00
Quick Ratio
9.50
Shares on Issue (Fully Dilluted)
292m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.14
Date | Announcements |
---|---|
23 July 24 |
June 2024 Quarterly Activities Report and Appendix 4C
×
June 2024 Quarterly Activities Report and Appendix 4C |
28 May 24 |
Noxopharm joins global Alliance for mRNA Medicines
×
Noxopharm joins global Alliance for mRNA Medicines |
14 May 24 |
Milestone reached as SOF-SKN progresses to next level
×
Milestone reached as SOF-SKN progresses to next level |
29 April 24 |
March 2024 Quarterly Activities Report and Appendix 4C
×
March 2024 Quarterly Activities Report and Appendix 4C |
04 April 24 |
Tour de Cure Grant for Brain Cancer Research
×
Tour de Cure Grant for Brain Cancer Research |
27 February 24 |
Appendix 4D and Half Year 2024 Financial Report
×
Appendix 4D and Half Year 2024 Financial Report |
13 February 24 |
Noxopharm extends Hudson Institute strategic partnership
×
Noxopharm extends Hudson Institute strategic partnership |
22 January 24 |
December 2023 Quarterly Activities Report and Appendix 4C
×
December 2023 Quarterly Activities Report and Appendix 4C |
18 December 23 |
Notification of cessation of securities - NOX
×
Notification of cessation of securities - NOX |
18 December 23 |
Change of Director's Interest Notice - GM
×
Change of Director's Interest Notice - GM |
16 November 23 |
Noxopharm 2023 AGM Chair Address
×
Noxopharm 2023 AGM Chair Address |
16 November 23 |
Noxopharm 2023 AGM Corporate Presentation
×
Noxopharm 2023 AGM Corporate Presentation |
16 November 23 |
Noxopharm Enhances Cash Position via R&D Rebate
×
Noxopharm Enhances Cash Position via R&D Rebate |
16 November 23 |
Results of Meeting
×
Results of Meeting |
27 October 23 |
Unlisted Options Expiring on 16 December 2023
×
Unlisted Options Expiring on 16 December 2023 |
18 October 23 |
mRNA Vaccine Enhancer Shows Inflammation Reduction
×
mRNA Vaccine Enhancer Shows Inflammation Reduction |
13 October 23 |
September 2023 Activities Report and Appendix 4C
×
September 2023 Activities Report and Appendix 4C |
09 October 23 |
Response to ASX Query
×
Response to ASX Query |
04 October 23 |
US FDA grants Orphan Drug Designation for CRO-67
×
US FDA grants Orphan Drug Designation for CRO-67 |
03 October 23 |
Pause in Trading
×
Pause in Trading |
03 October 23 |
Trading Halt
×
Trading Halt |
28 September 23 |
2023 AGM Letter to Shareholders and Proxy
×
2023 AGM Letter to Shareholders and Proxy |
28 September 23 |
2023 AGM Notice of Meeting and Proxy
×
2023 AGM Notice of Meeting and Proxy |
28 September 23 |
Latest CRO-67 data shows success in reducing cancer growth
×
Latest CRO-67 data shows success in reducing cancer growth |
27 September 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.